Scilex Holding Co (SCLX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US80880W1062
Scilex Holding Co financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 30.25 m USD |
| Gross profit | 125.80 m USD |
| Operating income | -346.01 m USD |
| EBIT | -350.77 m USD |
| Net income | -374.05 m USD |
| Diluted EPS – continuing operations | -36.48 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Scilex Holding Co
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
More stocks
- Sintx Technologies, Inc. (SINT)
- Sky Quarry Inc. (SKYQ)
- Thunder Power Holdings, Inc. (AIEV)
- ACCENDRA HEALTH INC/VA/ (ACH)
- BullFrog AI Holdings, Inc. (BFRG)
- Greenland Technologies Holding Corp. (GTEC)
- SAFEGUARD SCIENTIFICS INC (SFES)
- BEASLEY BROADCAST GROUP INC (BBGI)
- ADM TRONICS UNLIMITED, INC. (ADMT)
- Quince Therapeutics, Inc. (QNCX)
- HYDROFARM HOLDINGS GROUP, INC. (HYFM)
- Nevada Canyon Gold Corp. (NGLD)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.